Free Trial

Revelation Biosciences (REVB) Insider Trading & Ownership

Revelation Biosciences logo
$2.80 +0.06 (+2.00%)
As of 11:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Revelation Biosciences (NASDAQ:REVB) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
2.30%
Number Of
Insiders Buying
(Last 3 Years)
1
Amount Of
Insider Buying
(Last 3 Years)
$30.07K
Number Of
Insiders Selling
(Last 3 Years)
2
Amount Of
Insider Selling
(Last 3 Years)
$31.65K
Get REVB Insider Trade Alerts

Want to know when executives and insiders are buying or selling Revelation Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

REVB Insider Buying and Selling by Quarter

Revelation Biosciences Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2023George F. TidmarshDirectorSell19$748.80$14,227.20  
10/16/2023George F TidmarshDirectorSell7$950.40$6,652.80  
9/28/2023George F TidmarshDirectorSell0$993.60$0.00  
9/18/2023George F TidmarshDirectorSell2$1,065.60$2,131.20  
9/14/2023George F TidmarshDirectorSell8$1,080.00$8,640.00  
4/17/2023George F TidmarshDirectorBuy18$1,670.40$30,067.20  
(Data available from 1/1/2013 forward)

REVB Insider Trading Activity - Frequently Asked Questions

The list of insiders at Revelation Biosciences includes George F Tidmarsh. Learn more on insiders at REVB.

2.30% of Revelation Biosciences stock is owned by insiders. Learn more on REVB's insider holdings.

The following insider sold REVB shares in the last 24 months: George F Tidmarsh ($17,424.00).

Insiders have sold a total of 36 Revelation Biosciences shares in the last 24 months for a total of $31,651.20 sold.

Revelation Biosciences Key Executives

  • Mr. James M. Rolke (Age 55)
    CEO & Director
    Compensation: $649.25k
  • Mr. Chester Stanley Zygmont III (Age 44)
    CFO & Corporate Secretary
    Compensation: $479.14k
  • Ms. Sandra Vedrick
    Vice President of Human Resources & Investor Relations
  • Ms. Carol Odle
    Senior Director of Clinical Projects


This page (NASDAQ:REVB) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners